What is the appropriate dosing regimen for ranolazine, including adjustments for renal or hepatic impairment?

Ranolazine Dosing

Start ranolazine extended-release at 500 mg twice daily, and titrate to 1000 mg twice daily based on symptom response; avoid use entirely in patients with liver cirrhosis, and use extreme caution (maximum 500 mg twice daily with close monitoring) in patients with moderate-severe renal impairment (CrCl <60 mL/min).

Standard Dosing

The therapeutic dose range for ranolazine extended-release is 500 mg to 1000 mg twice daily 1. Both doses demonstrate equivalent efficacy for chronic stable angina symptoms 1.

• Initial dose: 500 mg twice daily
• Maintenance dose: May increase to 1000 mg twice daily if needed for symptom control
• The drug exhibits modest non-linearity, with a 2.5-fold increase in peak concentration and 2.7-fold increase in exposure when doubling from 500 mg to 1000 mg twice daily 2

Critical Contraindications and Warnings

Hepatic Impairment

Ranolazine is absolutely contraindicated in patients with liver cirrhosis 33. This is non-negotiable. The FDA label explicitly states this contraindication because:

• Cirrhotic patients with mild hepatic impairment (Child-Pugh A) show 30% increased drug concentrations
• Moderate impairment (Child-Pugh B) shows 80% increased concentrations
• Most concerning: QT prolongation increases 3-fold in cirrhotic patients with mild-moderate impairment, disproportionate to the drug concentration increase 33

This creates an unacceptable risk of torsades de pointes. Do not use ranolazine in any patient with cirrhosis, regardless of severity 1.

Renal Impairment

Exercise extreme caution in renal impairment and avoid in severe renal disease (CrCl <30 mL/min). The evidence here is particularly concerning:

• A pharmacokinetic study in severe renal impairment was stopped early when 2 of 4 subjects developed acute renal failure after receiving ranolazine 33
• One patient required hemodialysis; the other two improved only after drug discontinuation
• Drug exposure increases 40-50% across all degrees of renal impairment (mild, moderate, severe) 34
• The increase in exposure correlates negatively with creatinine clearance 4

Practical approach for renal impairment:

• CrCl ≥60 mL/min: Standard dosing (500-1000 mg twice daily)
• CrCl 30-60 mL/min (moderate impairment): Start 500 mg twice daily; monitor renal function closely; avoid titration to 1000 mg twice daily
• CrCl <30 mL/min (severe impairment): Avoid ranolazine entirely given the risk of acute renal failure 33
• Hemodialysis patients: Do not use—pharmacokinetics are unpredictable, with hemodialysis removing 52-69% of the drug per session, creating highly variable exposures 5

Monitor renal function (creatinine, BUN, potassium) periodically in all patients with moderate-severe renal impairment, and discontinue immediately if acute renal failure develops 33.

Special Populations

Elderly Patients (≥75 years)

• Start at the low end of dosing range (500 mg twice daily) 33
• Patients ≥75 years have higher rates of adverse events, serious adverse events, and drug discontinuations compared to placebo 3
• One case report documented severe neurologic toxicity (dysarthria, dysmetria, hallucinations, tremors) in an 81-year-old with renal impairment on ranolazine 6
• Do not exceed 500 mg twice daily in patients >80 years old, especially with any degree of renal impairment 6

Heart Failure

• No dose adjustment required for heart failure (NYHA Class I-IV) 33
• Ranolazine has minimal hemodynamic effects (no significant changes in heart rate or blood pressure) 1

Diabetes Mellitus

• No dose adjustment required 33
• Ranolazine produces small reductions in HbA1c, but should not be considered diabetes treatment 33
• May be particularly useful in diabetic patients with angina 1

Important Drug Interactions Affecting Dosing

CYP3A Inhibitors (Reduce Ranolazine Dose)

Ranolazine is extensively metabolized by CYP3A enzymes. Strong CYP3A inhibitors dramatically increase ranolazine exposure:

• Ketoconazole: Increases ranolazine exposure 3.9-fold 2
• Verapamil: Increases exposure approximately 2-fold 2
• Diltiazem 180 mg daily: Increases exposure 1.5-fold 2

When using moderate-strong CYP3A inhibitors, limit ranolazine to 500 mg twice daily maximum.

Digoxin (Monitor Levels)

Ranolazine increases digoxin concentrations by 40-60% through P-glycoprotein inhibition 12. Use with caution and monitor digoxin levels closely.

Clinical Context and Limitations

Important caveat: While ranolazine effectively reduces angina symptoms, it does not improve mortality or major cardiovascular outcomes 1. The RIVER-PCI trial showed no benefit for death, MI, or recurrent angina requiring revascularization in patients with incomplete revascularization 1. Similarly, the MERLIN trial found no benefit for cardiovascular death or MI in acute coronary syndrome 1.

Therefore, ranolazine should be reserved for symptomatic management of chronic stable angina when other antianginal agents are insufficient or contraindicated (e.g., patients with bradycardia, hypotension, or left ventricular hypertrophy where beta-blockers or calcium channel blockers are problematic) 17.

Monitoring Requirements

• QTc interval: Ranolazine causes dose-dependent QT prolongation 1. Baseline and periodic ECG monitoring is prudent, especially in patients at risk for arrhythmias
• Renal function: Monitor creatinine, BUN, and potassium periodically in patients with moderate-severe renal impairment 33
• Digoxin levels: If co-administered 1